Launch Date
10/14/2020
Credit Amount
0.00 Expired
Credit Expires
10/14/2021
Despite the high prevalence of hepatitis B virus (HBV) in the United States, only 32% of patients are aware of their HBV status and less than 30% receive treatment. There are six groups who are at especially high risk: foreign-born Asian/Pacific Islanders, Africa-born Black populations, incarcerated persons, people who inject drugs, men who have sex with men, and refugees. Disease awareness is especially low in many of these populations. In conjunction, the disease burden is compounded by cultural and societal barriers that often impede screening, prevention, and linkage to care.
This CME Outfitters podcast episode aims to provide learners with strategies to provide culturally appropriate counseling and support services to high-risk populations in order to optimize retention and long-term HBV care.
At the end of this CME/CE activity, participants should be able to provide culturally appropriate counseling and support services to patients to ensure understanding of their disease and promote retention in care.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, obstetricians/gynecologists, emergency department physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals, Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline, Inc.; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.
Dr. Martinez reports that he receives research support from AbbVie Inc.; Allergan; and Intercept Pharmaceuticals, Inc. He is on the advisory committee for AbbVie Inc.; and Gilead Sciences, Inc. He is on the Speakers Bureau for AbbVie Inc.; Dova Pharmaceuticals; Eisai Inc.; Gilead Sciences, Inc.; and Salix Pharmaceuticals. Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-138-H01-P.
Call us at 877.CME.PROS (877.263.7767).
PD-038-101420-47